ARTICLE | Clinical News
Octreolin octreotide acetate: Phase III data
February 16, 2015 8:00 AM UTC
An open-label, international Phase III trial in 155 adults with acromegaly showed that 65% of patients who received oral octreotide achieved the primary endpoint of maintaining IGF-1 levels of <1.3 t...